about
Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signalingMelanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancerEnabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panelTriple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancerMUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasionPIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.Dual specificity phosphatase 4 gene expression in association with triple-negative breast cancer outcome.Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution.ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancerA kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancerA gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistanceTrastuzumab has preferential activity against breast cancers driven by HER2 homodimers.The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epitheliumWITHDRAWN: Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma.Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma.TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint InhibitorsDiscordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification.Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistanceConditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer.Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.Intratumoral delivery of Paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulations.Fulminant Myocarditis with Combination Immune Checkpoint Blockade.Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.The genomic map of breast cancer: which roads lead to better targeted therapies?Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance.Association of FGFR1 with ERαmaintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer.Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling.In silico evaluation of DNA Damage Inducible Transcript 4 gene (DDIT4) as prognostic biomarker in several malignancies.EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.Do the genes tell us the path of most resistance?
P50
Q24296451-5608A11E-28CE-412D-9451-D991F5345CE0Q27853331-B97B419A-35BF-4FEE-A448-CB501E707FC9Q33263277-2FE7FA28-D156-47C5-90DE-677F49489427Q33445357-548697F3-1108-4092-92BD-E8C8A912D3E3Q33699641-BF8A2EF7-34FE-4A38-9517-2F98CC0DFDABQ33769821-746961E1-F88A-479A-A787-99192D0E12D2Q33875120-4CBBE6C4-37FA-4F5C-B168-FBEC085ED292Q33901817-8390296F-02AA-49CA-90F4-C74B5F0AB480Q34296476-83AACF6A-E4EE-4F29-9FF8-C3BB8930EFBFQ34357228-0D905D7F-3607-41ED-84DB-A4312CBBF450Q34979448-43E98DC7-B2A9-4549-876A-54601AEC8A78Q35140121-011F42B9-41E1-4F59-84A4-F0604ECA458CQ35479617-4AD3169E-C7E8-4129-AE8A-495FD0BA5FDBQ35501973-58A6C2FD-247C-426F-9274-D3AF4B18DD1CQ35566213-5213F5CE-45F5-4561-BB13-350F254D13BBQ35566231-A8EFC68B-8E7F-44F2-9015-ADABD32573F5Q35657873-DB659D48-B8B0-44B9-AA69-735F573A07C8Q36349099-7254ABB6-B3C7-438F-ABBC-2F83F8A665CBQ36382143-2D62ED44-FC65-4CE1-980F-BEAFBF644566Q36638173-137A4703-80B6-4E19-A8C5-ADFDC9A97A6AQ36693087-F5ACD773-74A7-4B03-ABAF-A33BE986FE23Q36929331-D4919308-1F91-48C3-8B0C-0548445EE88FQ36957198-4F1FD00B-3FF0-4EE8-A5D8-90C95C9EBB1CQ36986301-E19EA476-59BD-4C59-9F0B-B1321D1D38B9Q37055054-3920D634-2B05-41D3-9C10-43EBE1F46150Q37143534-6CDA4A48-AD4F-4200-8BFF-342A896F72E7Q37200831-FA9139D1-C616-400F-8F64-A89CE650F846Q37213277-7A037AEE-BB05-4C2C-9403-EB85AE68EA21Q37595462-8EFA2258-F38E-4C86-BA0F-F280C6CFF4E8Q37600589-9046C6DB-595A-492A-A0BF-CC03A17F1F90Q37691054-FB9386B1-7828-4BA0-8CD9-6F6A63B9F851Q37702328-1CFADE3E-59F6-4ED5-B09C-95538E89DA7DQ37721802-2106D65E-95BD-4FA3-A6CA-C20669B053C6Q38377528-137A95E5-CB40-4160-82DA-6829C3F637A3Q38631621-CFB39019-D650-4B51-BA52-869946C3D8BFQ38656592-50891F3A-326A-4401-B48F-C0B2ADAD7567Q38784424-128D86F1-E7B4-4869-847E-0B5AEA050D14Q38796904-E0651575-5962-4206-9D31-4C94AF9D5F6BQ38805633-EACB1A26-75CE-4A8D-9623-B174533598FDQ39603381-8B39F27D-EF3E-4331-84CE-ADFEB5EF4BDA
P50
description
medical researcher
@en
wetenschapper
@nl
name
Justin M. Balko
@en
Justin M. Balko
@nl
type
label
Justin M. Balko
@en
Justin M. Balko
@nl
altLabel
JM Balko
@en
prefLabel
Justin M. Balko
@en
Justin M. Balko
@nl
P101
P1416
P21
P31
P496
0000-0002-4263-5974